CPA
COLL icon

Capital Performance Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Capital Performance Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$850 – 705
2024
Q3 		$850 Buy
+22
New +$785 ﹤0.01% 1984

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Capital Performance Advisors's COLL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Collegium Pharmaceutical (COLL) in Q4 2024, closing a stake of 22 shares — an estimated $850 sold.

Capital Performance Advisors first reported a position in COLL in Q3 2024 and held it in 1 quarter. The position peaked at $850 in Q3 2024. 238 funds tracked by Wall St. Rank hold COLL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Collegium Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 22 Collegium Pharmaceutical shares in Q4 2024, an estimated $850.
  • Capital Performance Advisors first reported a position in Collegium Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Collegium Pharmaceutical position peaked at $850 in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.